Details
🎉Re-evaluating AL-ISS in the modern treatment era: GLS alone may not capture prognosis in advanced cardiac AL amyloidosis. Refining risk models remains essential.
📖 Read complete article:
Evaluating AL-ISS within a BNP-based model for AL amyloidosis in the daratumumab era | Blood Advances | American Society of Hematology https://ashpublications.org/bloodadvances/article/10/13/4612/567834/